Leviosa

Dexamethasone and Levofloxacin, the active ingredients in Leviosa, are a corticosteroid and a fluoroquinolone antibiotic presented as an ophthalmic solution for ocular use. They reduce inflammation and inhibit bacterial growth, making the product suitable for treating bacterial conjunctivitis, post‑operative ocular inflammation, and mixed bacterial‑inflammatory eye conditions in adult patients.

GNH USA supplies Leviosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU pharmacopeial standards and is distributed under strict quality‑assured conditions.

Leviosa acts on ocular inflammatory and bacterial pathways to manage mixed eye conditions.

Bacterial conjunctivitis: reduces bacterial load and associated inflammation. Post‑operative ocular inflammation: controls inflammation after eye surgery while preventing infection. Mixed bacterial‑inflammatory eye conditions: provides combined anti‑inflammatory and antibacterial therapy in a single formulation.

Leviosa may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Transient burning or stinging sensation upon instillation. - Temporary blurred vision. - Mild conjunctival hyperemia. - Increased intra‑ocular pressure (mild). - Headache. - Allergic conjunctivitis (mild).

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis. - Corneal ulceration or perforation. - Significant rise in intra‑ocular pressure leading to glaucoma. - Development of resistant bacterial strains. - Cataract formation with prolonged use. - Systemic corticosteroid effects such as hyperglycemia.

When prescribing Leviosa, clinicians should consider several precautionary measures to ensure safe use.

Assess infection type: confirm bacterial etiology before use. Monitor intra‑ocular pressure: especially in steroid‑responsive patients. Avoid in viral or fungal eye infections: may worsen condition. Use with caution in patients with known hypersensitivity to corticosteroids or fluoroquinolones. Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. Store below 25°C: keep in original container, protect from light and moisture.

Leviosa can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent use of other potent topical corticosteroids: may increase risk of ocular hypertension and cataract. - Systemic fluoroquinolones with QT‑prolonging drugs: may potentiate cardiac arrhythmia risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may reduce anti‑inflammatory effect. - Anticholinergic eye medications: may affect pupil size and intra‑ocular pressure.